- Home
- PPBT vs NCNA Comparison
PPBT vs NCNA Comparison
Compare PPBT & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- NCNA
- Stock Information
- Founded
- PPBT 2010
- NCNA 1997
- Country
- PPBT Israel
- NCNA United Kingdom
- Employees
- PPBT N/A
- NCNA N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- NCNA Health Care
- Exchange
- PPBT Nasdaq
- NCNA Nasdaq
- Market Cap
- PPBT 7.4M
- NCNA 7.6M
- IPO Year
- PPBT N/A
- NCNA 2017
- Fundamental
- Price
- PPBT $0.71
- NCNA $3.41
- Analyst Decision
- PPBT Strong Buy
- NCNA
- Analyst Count
- PPBT 1
- NCNA 0
- Target Price
- PPBT $33.00
- NCNA N/A
- AVG Volume (30 Days)
- PPBT 21.8M
- NCNA 205.1K
- Earning Date
- PPBT 11-14-2025
- NCNA 11-13-2025
- Dividend Yield
- PPBT N/A
- NCNA N/A
- EPS Growth
- PPBT N/A
- NCNA N/A
- EPS
- PPBT N/A
- NCNA N/A
- Revenue
- PPBT N/A
- NCNA N/A
- Revenue This Year
- PPBT N/A
- NCNA N/A
- Revenue Next Year
- PPBT N/A
- NCNA N/A
- P/E Ratio
- PPBT N/A
- NCNA N/A
- Revenue Growth
- PPBT N/A
- NCNA N/A
- 52 Week Low
- PPBT $0.53
- NCNA $2.78
- 52 Week High
- PPBT $13.95
- NCNA $330.00
- Technical
- Relative Strength Index (RSI)
- PPBT 45.98
- NCNA 38.82
- Support Level
- PPBT $0.71
- NCNA $3.55
- Resistance Level
- PPBT $0.89
- NCNA $3.86
- Average True Range (ATR)
- PPBT 0.13
- NCNA 0.28
- MACD
- PPBT 0.01
- NCNA -0.05
- Stochastic Oscillator
- PPBT 17.37
- NCNA 16.67
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.